Pretransplant evaluation and the risk of glucose metabolic alterations after renal transplantation: a prospective study.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
28 02 2023
Historique:
received: 16 05 2022
pubmed: 10 9 2022
medline: 4 3 2023
entrez: 9 9 2022
Statut: ppublish

Résumé

Post-transplant prediabetes (PreDM) and diabetes (PTDM) are common and have an impact on cardiovascular events. We sought to investigate the pathogenesis and best approach for prediction. We prospectively studied 115 waitlisted patients from a single center without manifest diabetes. An oral glucose tolerance test (OGTT) was performed yearly until transplantation and 12 months later. Insulin secretion, insulin sensitivity (IS) and disposition index (DI) were derived from the OGTT. PreDM and PTDM were observed in 27% and 28.6% of patients, respectively. Pretransplant age, body mass index (BMI), 120 min glucose, IS, DI, and prediabetes or undiagnosed diabetes were significantly associated with these alterations. In multivariate analysis, pretransplant age [odds ratio (OR) 1.5; 95% confidence interval (CI) 1.04-2.1], BMI (OR 1.16; 95% CI 1.04-1.3) and cumulative steroids (OR 1.5; 95% CI 1.02-2.2) were predictors of PreDM or PTDM. Receiver operating characteristic curve analysis showed that pretransplant BMI and 120 min glucose had the highest area under the curve (0.72; 95% CI 0.62-0.8; and 0.69; 95% CI 0.59-0.79, respectively). The highest discrimination cut-off for BMI (≥28.5 kg/m2) and 120 min glucose (≥123.5 mg/dL) yielded a similar number needed to diagnose (2.5). PreDM or PTDM develops in waitlisted patients with an ineffective insulin secretion and BMI shows a similar diagnostic capacity to OGTT. Pretransplant interventions may reduce post-transplant glucose alterations.

Sections du résumé

BACKGROUND
Post-transplant prediabetes (PreDM) and diabetes (PTDM) are common and have an impact on cardiovascular events. We sought to investigate the pathogenesis and best approach for prediction.
METHODS
We prospectively studied 115 waitlisted patients from a single center without manifest diabetes. An oral glucose tolerance test (OGTT) was performed yearly until transplantation and 12 months later. Insulin secretion, insulin sensitivity (IS) and disposition index (DI) were derived from the OGTT.
RESULTS
PreDM and PTDM were observed in 27% and 28.6% of patients, respectively. Pretransplant age, body mass index (BMI), 120 min glucose, IS, DI, and prediabetes or undiagnosed diabetes were significantly associated with these alterations. In multivariate analysis, pretransplant age [odds ratio (OR) 1.5; 95% confidence interval (CI) 1.04-2.1], BMI (OR 1.16; 95% CI 1.04-1.3) and cumulative steroids (OR 1.5; 95% CI 1.02-2.2) were predictors of PreDM or PTDM. Receiver operating characteristic curve analysis showed that pretransplant BMI and 120 min glucose had the highest area under the curve (0.72; 95% CI 0.62-0.8; and 0.69; 95% CI 0.59-0.79, respectively). The highest discrimination cut-off for BMI (≥28.5 kg/m2) and 120 min glucose (≥123.5 mg/dL) yielded a similar number needed to diagnose (2.5).
CONCLUSIONS
PreDM or PTDM develops in waitlisted patients with an ineffective insulin secretion and BMI shows a similar diagnostic capacity to OGTT. Pretransplant interventions may reduce post-transplant glucose alterations.

Identifiants

pubmed: 36083994
pii: 6695005
doi: 10.1093/ndt/gfac256
doi:

Substances chimiques

Glucose IY9XDZ35W2
Blood Glucose 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

778-786

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.

Auteurs

Arminda Fariña-Hernández (A)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Domingo Marrero-Miranda (D)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Estefania Perez-Carreño (E)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Antonia De Vera-Gonzalez (A)

Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.

Alejandra González (A)

Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.

Cristian Acosta-Sorensen (C)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Ana Elena Rodríguez-Rodríguez (AE)

Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Tenerife, Spain.

Tatiana Collantes (T)

Hospital Clínico de la Pontificia Universidad Católica de Chile.

Marta Del Pino García (MDP)

Pediatric Service, Hospital Universitario de Canarias, Tenerife, Spain.

Ana Isabel Rodríguez-Muñoz (AI)

Nephrology Service, Hospital Universitario NS de La Candelaria, Tenerife, Spain.

Carla Rodriguez-Alvarez (C)

Nephrology Service, Hospital Universitario NS de La Candelaria, Tenerife, Spain.

Antonio Rivero (A)

Nephrology Service, Hospital Universitario NS de La Candelaria, Tenerife, Spain.

Manuel Macía (M)

Nephrology Service, Hospital Universitario NS de La Candelaria, Tenerife, Spain.

Elena Teran (E)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Nuria V Sanchez-Dorta (NV)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Lourdes Perez-Tamajón (L)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Alejandra Alvarez-González (A)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Ana González-Rinne (A)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Aurelio Rodríguez-Hernández (A)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Eduardo De Bonis-Redondo (E)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Concepción Rodriguez-Adanero (C)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.

Domingo Hernández (D)

Nephrology Service, Hospital Regional Universitario de Málaga, Universidad de Málaga, IBIMA.

Esteban Porrini (E)

Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Tenerife, Spain.

Armando Torres (A)

Nephrology Service, Hospital Universitario de Canarias, Tenerife, Spain.
Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Tenerife, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH